Response and Adverse Event Rates With Placebo in Compensated MASH-related Cirrhosis: A Meta-analysis.
作者信息
Amaral Marcio J M, Moura Felipe S, Lima Luan C V, Souza Matheus
机构信息
Department of Internal Medicine, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
出版信息
J Clin Exp Hepatol. 2025 May-Jun;15(3):102487. doi: 10.1016/j.jceh.2024.102487. Epub 2024 Dec 16.
Abstract
摘要
相似文献
1
Response and Adverse Event Rates With Placebo in Compensated MASH-related Cirrhosis: A Meta-analysis.代偿期MASH相关肝硬化中安慰剂的反应率和不良事件发生率：一项荟萃分析
J Clin Exp Hepatol. 2025 May-Jun;15(3):102487. doi: 10.1016/j.jceh.2024.102487. Epub 2024 Dec 16.
2
Efruxifermin in Compensated Liver Cirrhosis Caused by MASH.艾弗鲁西费明用于治疗MASH引起的代偿期肝硬化。
N Engl J Med. 2025 Jun 26;392(24):2413-2424. doi: 10.1056/NEJMoa2502242. Epub 2025 May 9.
3
NASH-CHECK patient-reported outcome instrument: evaluation of content and face validity for patients with metabolic dysfunction-associated steatohepatitis and compensated cirrhosis.NASH-CHECK患者报告结局量表：对代谢功能障碍相关脂肪性肝炎和代偿期肝硬化患者的内容效度和表面效度评估
J Patient Rep Outcomes. 2025 Jul 1;9(1):76. doi: 10.1186/s41687-025-00881-6.
4
Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2b trial.地那非司他治疗代谢相关脂肪性肝炎：一项多中心、双盲、随机、安慰剂对照、2b 期临床试验。
Lancet Gastroenterol Hepatol. 2024 Dec;9(12):1090-1100. doi: 10.1016/S2468-1253(24)00246-2. Epub 2024 Oct 11.
5
Granulocyte colony-stimulating factor with or without stem or progenitor cell or growth factors infusion for people with compensated or decompensated advanced chronic liver disease.粒细胞集落刺激因子联合或不联合干细胞或祖细胞或生长因子输注治疗代偿期或失代偿期晚期慢性肝病患者。
Cochrane Database Syst Rev. 2023 Jun 6;6(6):CD013532. doi: 10.1002/14651858.CD013532.pub2.
6
Effect on lipid profile and clinical outcomes of obeticholic acid for the treatment of primary biliary cholangitis and metabolic dysfunction-associated steatohepatitis: A systematic review and meta-analysis.奥贝胆酸治疗原发性胆汁性胆管炎和代谢相关脂肪性肝炎对血脂谱和临床结局的影响：系统评价和荟萃分析。
Clin Res Hepatol Gastroenterol. 2023 Dec;47(10):102227. doi: 10.1016/j.clinre.2023.102227. Epub 2023 Oct 24.
7
Effect of dapagliflozin on metabolic dysfunction-associated steatohepatitis: multicentre, double blind, randomised, placebo controlled trial.达格列净对代谢功能障碍相关脂肪性肝炎的影响：多中心、双盲、随机、安慰剂对照试验。
BMJ. 2025 Jun 4;389:e083735. doi: 10.1136/bmj-2024-083735.
8
Statin Therapy is Associated With Lower Risk of Mortality Among Liver Transplant Candidates With Metabolic Dysfunction-associated Steatohepatitis.他汀类药物治疗与代谢功能障碍相关脂肪性肝炎的肝移植受者死亡率降低相关。
J Clin Exp Hepatol. 2025 Mar-Apr;15(2):102427. doi: 10.1016/j.jceh.2024.102427. Epub 2024 Oct 16.
9
Response and Adverse Event Rates With Placebo in Gastroparesis: A Systematic Review and Meta-analysis.安慰剂在胃轻瘫中的反应和不良事件发生率：系统评价和荟萃分析。
Clin Gastroenterol Hepatol. 2023 Jun;21(6):1447-1461. doi: 10.1016/j.cgh.2022.09.033. Epub 2022 Oct 19.
10
L-ornithine L-aspartate for prevention and treatment of hepatic encephalopathy in people with cirrhosis.L-鸟氨酸L-天冬氨酸用于预防和治疗肝硬化患者的肝性脑病。
Cochrane Database Syst Rev. 2018 May 15;5(5):CD012410. doi: 10.1002/14651858.CD012410.pub2.
本文引用的文献
1
A roadmap for clinical trials in MASH-related compensated cirrhosis.MASH 相关代偿性肝硬化临床试验路线图。
Nat Rev Gastroenterol Hepatol. 2024 Nov;21(11):809-823. doi: 10.1038/s41575-024-00955-8. Epub 2024 Jul 17.
2
Resmetirom: First Approval.雷美替胺：首次获批
Drugs. 2024 Jun;84(6):729-735. doi: 10.1007/s40265-024-02045-0. Epub 2024 May 21.
3
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.一项评估 Resmetirom 治疗伴有肝纤维化的 NASH 的 3 期随机对照试验。
N Engl J Med. 2024 Feb 8;390(6):497-509. doi: 10.1056/NEJMoa2309000.
4
A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosis.一项在伴有 NASH 和代偿性肝硬化的患者中进行的aldafermin 的随机、双盲、安慰剂对照试验。
Hepatology. 2024 Mar 1;79(3):674-689. doi: 10.1097/HEP.0000000000000607. Epub 2023 Sep 21.
5
Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Compensated Cirrhosis (FALCON 2): A Randomized Phase 2b Study.佩格司他丁治疗非酒精性脂肪性肝炎和代偿性肝硬化患者（FALCON 2）：一项随机 2b 期研究。
Clin Gastroenterol Hepatol. 2024 Jan;22(1):113-123.e9. doi: 10.1016/j.cgh.2023.04.012. Epub 2023 Apr 23.
6
Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial.每周一次给予 2.4 毫克司美格鲁肽治疗非酒精性脂肪性肝炎相关肝硬化患者：一项随机、安慰剂对照的 2 期临床试验。
Lancet Gastroenterol Hepatol. 2023 Jun;8(6):511-522. doi: 10.1016/S2468-1253(23)00068-7. Epub 2023 Mar 16.
7
Challenges and opportunities in NASH drug development.非酒精性脂肪性肝炎药物研发的挑战与机遇。
Nat Med. 2023 Mar;29(3):562-573. doi: 10.1038/s41591-023-02242-6. Epub 2023 Mar 9.
8
A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis.一项针对代偿性非酒精性脂肪性肝炎肝硬化患者的efruxifermin随机、双盲、安慰剂对照IIa期试验。
JHEP Rep. 2022 Aug 23;5(1):100563. doi: 10.1016/j.jhepr.2022.100563. eCollection 2023 Jan.
9
Placebo Adverse Events in Non-alcoholic Steatohepatitis Clinical Trials: A Pooled Analysis of 2,944 Participants.安慰剂不良反应在非酒精性脂肪性肝炎临床试验中的分析：2944 名参与者的汇总分析。
Am J Gastroenterol. 2023 Apr 1;118(4):645-653. doi: 10.14309/ajg.0000000000002042. Epub 2022 Sep 30.
10
Placebo effect on progression and regression in NASH: Evidence from a meta-analysis.安慰剂效应对 NASH 进展和缓解的影响：来自荟萃分析的证据。
Hepatology. 2022 Jun;75(6):1647-1661. doi: 10.1002/hep.32315. Epub 2022 Jan 24.
Zotero 插件